Nikos Kotsopoulos

Nikos Kotsopoulos

Auto-generated profile, based on publicly available information

Nikos Kotsopoulos

Global Market Access Solutions, Chardonne, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
NKNikos Kotsopoulos
Nikos Kotsopoulos
MCMark Connolly
Mark Connolly
Introduction Rising obesity prevalence is a health priority for many governments because of its impact on population health and economic consequences. We sought to estimate the broader consequences of obesity in Canada by applying a government perspective framework that captures lost tax revenues and increased government spending on social benefit programs. Methods An age-specific prevalence-based model was built to quantify the fiscal burden of disease for government attributed to people living with obesity. The model was populated with age-specific wages, employment activity and government benefits received to estimate taxes and transfer costs. A targeted literature search was conducted to identify modifiers of employment status, wages and disability status attributed to people with obesity, and applied to employment and epidemiological projections which enabled us to estimate government costs and tax losses. Government tax revenue and costs attributed to obesity were projected over a 10-year period and discounted at 3%. Results The fiscal burden of obesity in Canada is estimated at CAD$22,974 million (2021). This figure consists of obesity-attributed revenue losses of CAD$9404 million from direct taxes due to decreased employment activity and CAD$2374 million from indirect tax revenue losses due to reduced consumption taxes. Healthcare costs are estimated at CAD$7881 million annually and disability costs of CAD$3686 million annually. This fiscal burden of disease distributed amongst taxpayers in 2021 is estimated to be CAD$752 per capita. We estimate for every 1% reduction in obesity prevalence, CAD$229.7 million net fiscal gains can be achieved annually. Conclusions Obesity is associated with substantial clinical and economic burden not only to the healthcare system but also to wider government budgets as demonstrated using fiscal analysis. Reductions in obesity prevalence are likely to have positive fiscal gains for government from reduced spending on public benefits and increased tax revenue attributed to employment changes.

13 December 2024 in Human Reproduction
Verified
Journal Article
Open access
MCMei-Jou Chen
Mei-Jou Chen
NKNikos Kotsopoulos
Nikos Kotsopoulos
AYAmy Ming-Fang Yen
Amy Ming-Fang Yen
KLKuan-Ting Lin
Kuan-Ting Lin
MCMark Connolly
Mark Connolly
STUDY QUESTION: What is the governmental fiscal impact of a new assisted reproduction subsidy scheme based on projected lifetime net taxes attributed to resulting live births in Taiwan? SUMMARY ANSWER: We estimate that the new fertility reimbursement scheme has generated favorable lifetime fiscal gains for the Taiwanese government, resulting in a return on investment (ROI) of NT$5.6 for every NT$1.0 spent based on those families receiving public subsidies for fertility care under the new scheme. WHAT IS KNOWN ALREADY: Globally, there is variation in the amount of public reimbursement for assisted reproduction provided to infertile couples. Cost is an important consideration for many infertile couples that can influence the amount of services provided and the types of services used. STUDY DESIGN, SIZE, DURATION: The analysis is based on the number of live births resulting from those couples receiving public subsidies for assisted reproduction. The cohort is based on those children born between March 2022 and July 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: A lifetime fiscal model was developed to project age-specific lifetime tax revenue and age-dependent benefits likely received from government attributed to the children born. The analysis is based on age-specific projected earnings adjusted for work activity and applied to published income tax burden data, in addition to estimated indirect consumption taxes paid. Furthermore, we estimate the lifetime national insurance contributions per worker, including employer contributions. To account for changes over the modeling period, we increased wages based on historical economic growth, government benefits were increased based on the rate of consumer price inflation rate, and all costs and taxes were discounted at 3.5%. MAIN RESULTS AND THE ROLE OF CHANCE: A child born in Taiwan in 2022 is expected to pay discounted gross tax revenues of NT$7 257 438 and receive NT$5 373 730 in discounted future benefits from the government. Following implementation of the new funding policy, based on the number of resulting births, the cost per live birth is NT$331 918. Applying the cost per live birth, we estimate the discounted net tax revenue to be NT$1 551 789 for each child born from the subsidy. The ROI for the Taiwanese government is estimated at 568% over the lifetime of the IVF-conceived children. LIMITATIONS, REASONS FOR CAUTION: Several assumptions are applied in making long-term financial projections. Should economic conditions change dramatically, this could influence the projections described in our work. WIDER IMPLICATIONS OF THE FINDINGS: The results suggest the government benefits from public subsidy for fertility services when taking into consideration the long-term work activity of these children and future tax revenue generated for government. The results are broadly applicable to other markets, although variations in wages, lifetime work activity, and taxation rates would influence the conclusions reported here. STUDY FUNDING/COMPETING INTEREST(S): The work was sponsored by the Merck Group in Singapore (funding to N.K. and M.P.C.). The sponsoring organization was given an opportunity to review the final manuscript; however, the authors retained full editorial control over the final published materials. The authors hold no financial interests in the sponsoring company. N.K. and M.P.C. have received consulting fees from Merck and Organon and payment/honoraria from Merck. M.-J.C. received no funding for this work but has received honoraria for lectures from the Taiwanese Society for Reproduction Medicine, Taiwanese Association of Obstetrics and Gynecology, Japanese Society of Obstetrics and Gynecology, The Endocrine Society of the ROC, Merck, Organon, and Ferring; attendance fees for expert meetings from Health Promotion Administration, Ministry of Health and Welfare, Taiwan, and the National Science and Technology Council of Taiwan; and support for attending meetings and/or travel from the National Science and Technology Council of Taiwan and Merck. None of the other authors report any conflicts in relation to this work. TRIAL REGISTRATION NUMBER: N/A.

1 May 2025 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
APAna Teresa Paquete
Ana Teresa Paquete
UMUche Mordi
Uche Mordi
JJJames Jarrett
James Jarrett
RTRyan Thaliffdeen
Ryan Thaliffdeen
PCParesh Chaudhari
Paresh Chaudhari
PSPatrick S Sullivan
Patrick S Sullivan
Purpose: Investments in antiretroviral therapy (ART) have shown to improve outcomes for those living with human immunodeficiency virus (HIV) and reduce exposure to and transmission of the virus. In the current work, we assess the impact of ART on government public accounts since its introduction in 1987. Methods: National HIV epidemiological data from 1987 to 2023 were compared to a hypothetical no ART treatment scenario. This scenario was based on time series analysis, and on a transmission equation based on the effectiveness of ART. In the absence of historical epidemiological data, trend extrapolations were considered. The model assumes that individuals on ART are virally suppressed and, conservatively, excludes the impact of pre-exposure prophylaxis. The resulting differences in the number of HIV infections, acquired immunodeficiency syndrome (AIDS) cases and HIV-related deaths per year, were then considered to evaluate the impact on the labor market and on healthcare costs, based on the literature. The impact on employment was then used to estimate tax revenue and social benefits transfers. Results are presented separately with and without longevity effects. Results: The investment in ART from 1987 to 2023 was estimated to prevent millions of new infections and AIDS cases and to avoid HIV-related deaths. This investment was estimated to provide a return of US$2.11 trillion from 1987 to 2023; each US$1 spent on ART was estimated to create a revenue of US$4.3 to the public sector in the USA. Results remained positive when longevity effects were included. One-way sensitivity analysis showed results were robust. Conclusion: The analysis illustrates the broader economic benefits to the government attributed to public and private investments to develop and make ART available. The fiscal analysis of investing in ART shows a fourfold gain for the US government. This broader analysis is crucial to help shape health policy and funding decisions. Plain Language Summary: Treatments for human immunodeficiency virus (HIV) infection cost money to provide, but also can have positive economic effects by keeping people healthy, avoiding healthcare costs from HIV-related illnesses, and allowing people living with HIV to stay healthy and contribute to the workforce. To describe the overall impact of HIV treatments on the US public economy, we used historical data since antiretroviral therapy (ART) was first made available in the United States (US) for the treatment of HIV and compared it with a scenario in which ART was not available (1987– 2023). The aims were to consider the benefits of ART use for health outcomes and in the labor market and to quantify the overall costs and benefits to the US government. The impact of ART use in reducing the number of HIV infections, AIDS (acquired immunodeficiency syndrome) cases, HIV-related deaths and on improving the outcomes of those living with HIV was analyzed in terms of economic transfers to the government. More workers in the labor market attributed to using ART stopped the loss of tax revenue and the need for governmental payments, such as unemployment insurance and disability benefits. The reduction of healthcare costs for HIV care financed by the government was also considered. Our model suggests that public investment in the development of progressively more effective ART resulted in a net financial gain for the government since the mid 1990s, with a current gain of US$ 4.3 per every US$ 1 spent on ART and a net present value of US$ 2.11 trillion from 1987 to 2023. An analysis of the impact of healthcare public spending in broader economic sectors is essential to improve the evidence available to public decision makers.

18 October 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
MCMark Connolly
Mark Connolly
NKNikolaos Kotsopoulos
Nikolaos Kotsopoulos
CRCraig Roberts
Craig Roberts
LKLaurence Kotlikoff
Laurence Kotlikoff
DBDavid E. Bloom
David E. Bloom
MNMawuli Nyaku
Mawuli Nyaku
The emergence of COVID-19 has displayed the importance of immunization and the need for continued public investment in vaccination programs. Globally, national vaccination programs rely heavily on tax-financed expenditure, requiring upfront investments and ongoing financial commitments. To evaluate annual public investments, we conducted a fiscal analysis that quantifies the public economic consequences to government in the United States attributable to childhood vaccination. To estimate the change in net government revenue, we developed a decision-analytic model that quantifies lifetime tax revenues and transfers based on changes in morbidity and mortality arising from vaccination of the 2017 U.S. birth cohort. Reductions in deaths and comorbid conditions attributed to pediatric vaccines were used to derive gross lifetime earnings gains, tax revenue gains attributed to averted morbidity and mortality avoided, disability transfer cost savings, and averted special education costs associated with each vaccine. Our analysis indicates a fiscal dividend of $41.7 billion from vaccinating this cohort. The bulk of this gain for government reflects avoiding the loss of $30.6 billion in present-value tax revenues. All pediatric vaccines raise tax revenues by reducing vaccine-preventable morbidity and mortality in amounts ranging from $7.3 million (hepatitis A) to $20.3 billion (diphtheria) over the life course. Based on public investments in pediatric vaccines, a benefit-cost ratio of 17.8 was calculated for each dollar invested in childhood immunization. The public economic yield attributed to childhood vaccination in the U.S. is significant from a government perspective, providing fiscal justification for ongoing investment.

1 October 2025 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
CCCillian Copeland
Cillian Copeland
RMRui Martins
Rui Martins
RTRyan Thaliffdeen
Ryan Thaliffdeen
NKNikos Kotsopoulos
Nikos Kotsopoulos
JJJames Jarrett
James Jarrett
MPMaarten J. Postma
Maarten J. Postma
Background: The United States (US) HIV/AIDS strategy has targeted a 90% reduction in HIV infections by 2030. Whilst progress has been made in US HIV policy, the persistence of nearly 32,000 new infections annually highlights substantial barriers that still hinder effective treatment and the achievement of national targets. While the humanistic burden of HIV is well documented, there are broader economic effects on employment, disability and retirement. The objective of this study is to evaluate these economic gains when improving various HIV policies. Methodology: This analysis adapts a published Markov model assessing the role of six key policy parameters related to diagnosis, pre-exposure prophylaxis (PrEP) uptake, treatment initiation, and treatment as prevention (TasP) on the HIV epidemic in the US. Improvements in these parameters were explored to estimate averted HIV infections over 50 years and, subsequently, the feasibility of achieving the 2030 target of a 90% reduction in HIV incidence. A fiscal economic framework was also applied, linking HIV cases and policy targets to productivity, tax revenue, transfer benefits, and healthcare costs incurred by the US government. Results: Results were calculated for the general US population and for men who have sex with men (MSM), a subgroup experiencing a high HIV burden. For the general US population, policy improvements led to an average of 5,324 averted HIV infections annually over the 50-year horizon, corresponding to a total net annual fiscal gain of $397 million or $74,511 per averted infection. For the MSM subgroup, 911 infections were averted annually resulting in a net fiscal gain of $96 million, or $105,031 per averted infection. Conclusion: This analysis demonstrates that the benefits of HIV policy are not limited to the healthcare setting and show how initial investments provide long-term benefits by preventing HIV transmission and the associated impact on individuals’ labor market outcomes. While relying on assumptions and projections that may not capture all real-word complexities, fiscal analyses can provide a useful tool for policy evaluation that facilitate a holistic assessment of the wider costs and benefits that fall on governments as well as benefits of achieving policy targets.

1 July 2024 in Journal of Medical Economics
Verified
Journal Article
Open access
CCCillian Copeland
Cillian Copeland
NKNikos Kotsopoulos
Nikos Kotsopoulos
AFAndrea Favre-Bulle
Andrea Favre-Bulle
GBGoran Bencina
Goran Bencina
DSDemet Sönmez
Demet Sönmez
SSStina Salomonsson
Stina Salomonsson
Triple Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer that can impact patients' employment and workforce participation. This study estimates how the employment effects of TNBC impact government tax revenue and public benefits expenditure in Switzerland, representing the fiscal burden of disease (FBoD), and likely consequences of introducing new treatment options. A four-state cohort model was used to calculate fiscal effects for two treatments: Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab monotherapy (P + C→P) and neoadjuvant chemotherapy alone (C). Lifetime present values of tax revenue, social benefit payments and healthcare costs were calculated for the average population and those undergoing treatment to assess the FBoD. An average TNBC patient treated with C and P + C→P is expected to generate CHF128,999 and CHF97,008 less tax than the average population, respectively, and require increased social benefit payments. Compared to C, 75% of the incremental healthcare costs of P + C→P are estimated to be offset through tax revenue gains. This analysis demonstrates that 75% of the additional costs of a new TNBC treatment option can be offset by gains in tax revenue. Fiscal analysis can be a useful tool to complement existing methods for evaluating new treatments.